Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242


Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.

Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, Ojo NC, Caldwell K, Abhyankar J, Boucher T, Hart MG, Makarov V, Montpreville VT, Mercier O, Chan TA, Scagliotti G, Bironzo P, Novello S, Karachaliou N, Rosell R, Anderson I, Gabrail N, Hrom J, Limvarapuss C, Choquette K, Spira A, Rousseau R, Voong C, Rizvi NA, Fadel E, Frattini M, Jooss K, Skoberne M, Francis J, Yelensky R.

Nat Biotechnol. 2018 Dec 17. doi: 10.1038/nbt.4313. [Epub ahead of print]


Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis.

Garassino MC, Kawaguchi T, Gregorc V, Rulli E, Ando M, Marsoni S, Isa SI, Novello S, Farina G, Barni S, Torri V, Cinquini M.

ESMO Open. 2018 Nov 1;3(6):e000327. doi: 10.1136/esmoopen-2018-000327. eCollection 2018. Review.


Corrigendum to "Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario" [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150-156].

Addeo A, Tabbò F, Robinson T, Buffoni L, Novello S.

Crit Rev Oncol Hematol. 2018 Nov 2. pii: S1040-8428(18)30288-9. doi: 10.1016/j.critrevonc.2018.06.018. [Epub ahead of print] No abstract available.


The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: An integrative review of evidence, mechanisms, and clinical implications.

Fornaro M, Anastasia A, Novello S, Fusco A, Pariano R, De Berardis D, Solmi M, Veronese N, Stubbs B, Vieta E, Berk M, de Bartolomeis A, Carvalho AF.

Pharmacol Res. 2018 Oct 29. pii: S1043-6618(18)31201-5. doi: 10.1016/j.phrs.2018.10.025. [Epub ahead of print] Review.


Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.

Marandino L, La Salvia A, Sonetto C, De Luca E, Pignataro D, Zichi C, Di Stefano RF, Ghisoni E, Lombardi P, Mariniello A, Reale ML, Trevisi E, Leone G, Muratori L, Marcato M, Bironzo P, Novello S, Aglietta M, Scagliotti GV, Perrone F, Di Maio M.

Ann Oncol. 2018 Oct 10. doi: 10.1093/annonc/mdy449. [Epub ahead of print]


Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.

Gardoni F, Morari M, Kulisevsky J, Brugnoli A, Novello S, Pisanò CA, Caccia C, Mellone M, Melloni E, Padoani G, Sosti V, Vailati S, Keywood C.

J Pharmacol Exp Ther. 2018 Dec;367(3):442-451. doi: 10.1124/jpet.118.251645. Epub 2018 Oct 5.


Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv192-iv237. doi: 10.1093/annonc/mdy275. No abstract available.


Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators.

N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.


Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal.

Pelosi G, Papotti M, Righi L, Rossi G, Ferrero S, Bosari S, Calabrese F, Kern I, Maisonneuve P, Sonzogni A, Albini A, Harari S, Barbieri F, Capelletto E, Catino AM, Cavone D, De Palma A, Fusco N, Lunardi F, Maiorano E, Marzullo A, Novello S, Papanikolaou N, Pasello G, Pennella A, Pezzuto F, Punzi A, Prisciandaro E, Rea F, Rosso L, Scattone A, Serio G.

J Thorac Oncol. 2018 Nov;13(11):1750-1761. doi: 10.1016/j.jtho.2018.07.002. Epub 2018 Jul 7.


A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics.

Ferrer L, Giaj Levra M, Brevet M, Antoine M, Mazieres J, Rossi G, Chiari R, Westeel V, Poudenx M, Letreut J, Gervais R, Osman G, Girard N, Toffart AC, Novello S, Moro-Sibilot D.

J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33044-2. doi: 10.1016/j.jtho.2018.08.2028. [Epub ahead of print]


The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: A plea for further research attention.

Fornaro M, De Berardis D, Anastasia A, Novello S, Fusco A, Cattaneo CI, Solmi M, Monaco F, Veronese N, Kim YK, de Bartolomeis A.

Psychiatry Res. 2018 Nov;269:658-672. doi: 10.1016/j.psychres.2018.08.034. Epub 2018 Aug 16. Review.


Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.

Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nüesch E, Balas B, Camidge DR.

Ann Oncol. 2018 Nov 1;29(11):2214-2222. doi: 10.1093/annonc/mdy405.


G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.

Novello S, Arcuri L, Dovero S, Dutheil N, Shimshek DR, Bezard E, Morari M.

Neurobiol Dis. 2018 Dec;120:21-33. doi: 10.1016/j.nbd.2018.08.018. Epub 2018 Aug 30.


Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer.

Turkaj A, Morelli AM, Vavalà T, Novello S.

Front Oncol. 2018 Jul 27;8:278. doi: 10.3389/fonc.2018.00278. eCollection 2018. Review.


Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, Hirsh V, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV.

Oncologist. 2018 Aug 23. pii: theoncologist.2018-0089. doi: 10.1634/theoncologist.2018-0089. [Epub ahead of print]


Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study.

Reck M, Mellemgaard A, Novello S, Postmus PE, Gaschler-Markefski B, Kaiser R, Buchner H.

Onco Targets Ther. 2018 Aug 6;11:4573-4582. doi: 10.2147/OTT.S170722. eCollection 2018.


Alleged malpractice in orthopaedics. Analysis of a series of medmal insurance claims.

Casali MB, Blandino A, Del Sordo S, Vignali G, Novello S, Travaini G, Berlusconi M, Genovese U.

J Orthop Traumatol. 2018 Jul 27;19(1):7. doi: 10.1186/s10195-018-0500-4.


Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.


Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy.

Vavalà T, Novello S.

Ther Adv Med Oncol. 2018 Aug 3;10:1758835918789364. doi: 10.1177/1758835918789364. eCollection 2018. Review.


NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.

Gregorc V, Cavina R, Novello S, Grossi F, Lazzari C, Capelletto E, Genova C, Salini G, Lambiase A, Santoro A.

Oncologist. 2018 Oct;23(10):1133-e112. doi: 10.1634/theoncologist.2018-0292. Epub 2018 Aug 3.


Immunotherapy & thoracic cancers.

Rossi A, Novello S.

J Thorac Dis. 2018 May;10(Suppl 13):S1425-S1426. doi: 10.21037/jtd.2017.12.137. No abstract available.


Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.

Tozzi A, Durante V, Bastioli G, Mazzocchetti P, Novello S, Mechelli A, Morari M, Costa C, Mancini A, Di Filippo M, Calabresi P.

Neurobiol Dis. 2018 Oct;118:1-8. doi: 10.1016/j.nbd.2018.06.008. Epub 2018 Jun 13.


Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N.

Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196.


Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.

Augeri S, Capano S, Morone S, Fissolo G, Giacomino A, Peola S, Drace Z, Rapa I, Novello S, Volante M, Righi L, Ferrero E, Ortolan E, Funaro A.

Oncotarget. 2018 Apr 27;9(32):22785-22801. doi: 10.18632/oncotarget.25237. eCollection 2018 Apr 27.


Circulating levels of mannose-binding lectin (MBL) in age-related macular degeneration.

Pradella FM, Nisihara R, Sato MT, Grandinetti AA, Novello SB, Pires M, Schebelski D, Messias-Reason I.

Arq Bras Oftalmol. 2018 Apr;81(2):120-124. doi: 10.5935/0004-2749.20180027.


Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.

Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N.

Clin Lung Cancer. 2018 Jul;19(4):331-339. doi: 10.1016/j.cllc.2018.03.014. Epub 2018 Mar 21. Review.


NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.

Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M.

Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.


Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.

Kopecka J, Salaroglio IC, Righi L, Libener R, Orecchia S, Grosso F, Milosevic V, Ananthanarayanan P, Ricci L, Capelletto E, Pradotto M, Napoli F, Di Maio M, Novello S, Rubinstein M, Scagliotti GV, Riganti C.

Lung Cancer. 2018 Jun;120:34-45. doi: 10.1016/j.lungcan.2018.03.022. Epub 2018 Mar 26.


Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial.

Lee CK, Novello S, Rydén A, Mann H, Mok T.

J Clin Oncol. 2018 Jun 20;36(18):1853-1860. doi: 10.1200/JCO.2017.77.2293. Epub 2018 May 7.


The Tradition of the Rising Sun: When Geography Counts.

Rossi A, Novello S.

J Thorac Oncol. 2018 May;13(5):598-600. doi: 10.1016/j.jtho.2018.03.006. No abstract available.


Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.

Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J.

Ann Oncol. 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121.


Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators.

N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.


Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants.

Fornaro M, Anastasia A, Monaco F, Novello S, Fusco A, Iasevoli F, De Berardis D, Veronese N, Solmi M, de Bartolomeis A.

J Affect Disord. 2018 Jul;234:131-138. doi: 10.1016/j.jad.2018.02.085. Epub 2018 Mar 1.


Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.

Levy A, Faivre-Finn C, Hasan B, De Maio E, Berghoff AS, Girard N, Greillier L, Lantuéjoul S, O'Brien M, Reck M, Dingemans AC, Novello S, Berghmans T, Besse B, Hendriks L; Young Investigators EORTC Lung Cancer Group (YI EORTC LCG).

Eur J Cancer. 2018 Apr;93:37-46. doi: 10.1016/j.ejca.2018.01.067. Epub 2018 Feb 21.


Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.

Addeo A, Tabbò F, Robinson T, Buffoni L, Novello S.

Crit Rev Oncol Hematol. 2018 Feb;122:150-156. doi: 10.1016/j.critrevonc.2017.12.015. Epub 2017 Dec 30. Review. Erratum in: Crit Rev Oncol Hematol. 2018 Nov 2;:.


Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis.

Fornaro M, Anastasia A, Novello S, Fusco A, Solmi M, Monaco F, Veronese N, De Berardis D, de Bartolomeis A.

Bipolar Disord. 2018 May;20(3):195-227. doi: 10.1111/bdi.12612. Epub 2018 Feb 14. Review.


Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.

Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R.

Oncoimmunology. 2017 Nov 27;7(3):e1398874. doi: 10.1080/2162402X.2017.1398874. eCollection 2018.


Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician's perspective.

Fornaro M, Kardash L, Novello S, Fusco A, Anastasia A, De Berardis D, Perna G, Carta MG.

Expert Opin Drug Discov. 2018 Mar;13(3):221-228. doi: 10.1080/17460441.2018.1428554. Epub 2018 Jan 22.


Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey.

Carnio S, Galetta D, Scotti V, Cortinovis DL, Antonuzzo A, Pisconti S, Rossi A, Martelli O, Cecere FL, Lunghi A, Del Conte A, Montagna ES, Topulli J, Pelizzoni D, Rapetti SG, Gianetta M, Pacchiana MV, Pegoraro V, Cataldo N, Bria E, Novello S.

Support Care Cancer. 2018 Jun;26(6):1841-1849. doi: 10.1007/s00520-017-4004-1. Epub 2017 Dec 21.


Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment.

Pilotto S, Sperduti I, Leuzzi G, Chiappetta M, Mucilli F, Ratto GB, Lococo F, Filosso PL, Spaggiari L, Novello S, Milella M, Santo A, Scarpa A, Infante M, Tortora G, Facciolo F, Bria E.

J Thorac Oncol. 2018 Apr;13(4):568-575. doi: 10.1016/j.jtho.2017.12.003. Epub 2017 Dec 18.


Predictors of hospitalization length of stay among re-admitted treatment-resistant Bipolar Disorder inpatients.

Fornaro M, Iasevoli F, Novello S, Fusco A, Anastasia A, De Berardis D, Valchera A, de Bartolomeis A.

J Affect Disord. 2018 Mar 1;228:118-124. doi: 10.1016/j.jad.2017.12.009. Epub 2017 Dec 7.


Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisanò CA, Morella I, Fasano S, Journigan BV, Meyer ME, Polgar WE, Brambilla R, Zaveri NT, Morari M.

Br J Pharmacol. 2018 Mar;175(5):782-796. doi: 10.1111/bph.14123. Epub 2018 Jan 31.


Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.

Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N.

J Thorac Oncol. 2018 Feb;13(2):165-183. doi: 10.1016/j.jtho.2017.11.111. Epub 2017 Nov 23. Review.


Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.

Morari M, Brugnoli A, Pisanò CA, Novello S, Caccia C, Melloni E, Padoani G, Vailati S, Sardina M.

J Pharmacol Exp Ther. 2018 Feb;364(2):198-206. doi: 10.1124/jpet.117.245100. Epub 2017 Nov 22.


Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer.

Gobbini E, Pilotto S, Pasello G, Polo V, Di Maio M, Arizio F, Galetta D, Petrillo P, Chiari R, Matocci R, Di Costanzo A, Di Stefano TS, Aglietta M, Cagnazzo C, Sperduti I, Bria E, Novello S.

Clin Lung Cancer. 2018 Mar;19(2):191-198. doi: 10.1016/j.cllc.2017.10.012. Epub 2017 Oct 28.


Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.

Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV.

J Thorac Oncol. 2018 Jan;13(1):124-133. doi: 10.1016/j.jtho.2017.09.1968. Epub 2017 Oct 24.


Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G.

J Clin Oncol. 2017 Nov 1;35(31):3591-3600. doi: 10.1200/JCO.2017.72.9012. Epub 2017 Sep 11.


Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

Gobbini E, Galetta D, Tiseo M, Graziano P, Rossi A, Bria E, Di Maio M, Rossi G, Gregorc V, Riccardi F, Scotti V, Ceribelli A, Buffoni L, Delmonte A, Franchina T, Migliorino MR, Cortinovis D, Pisconti S, Bordi P, Catino A, Maiello E, Arizio F, Novello S; other Co-Authors.

Lung Cancer. 2017 Sep;111:30-37. doi: 10.1016/j.lungcan.2017.06.009. Epub 2017 Jun 16.


Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup.

Garrido P, Chouaki N, Serke M, Giraud P, Ricardi U, Vallejo C, Visseren-Grul C, Soldatenkova V, Novello S.

ESMO Open. 2017 Mar 9;2(1):e000141. doi: 10.1136/esmoopen-2016-000141. eCollection 2017. No abstract available.


Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.

Gaschler-Markefski B, Sikken P, Heymach JV, Gottfried M, Mellemgaard A, Novello S, Gann CN, Barrueco J, Reck M, Hanna NH, Kaiser R.

ESMO Open. 2017 Apr 11;2(1):e000102. doi: 10.1136/esmoopen-2016-000102. eCollection 2017.

Supplemental Content

Loading ...
Support Center